Daiichi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI, and what generic alternatives to DAIICHI drugs are available?
DAIICHI has four approved drugs.
There are twenty-five US patents protecting DAIICHI drugs.
There are three hundred and nineteen patent family members on DAIICHI drugs in forty-five countries and twenty-five supplementary protection certificates in sixteen countries.
Summary for Daiichi
International Patents: | 319 |
US Patents: | 25 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 4 |
PTAB Cases with Daiichi as patent owner: | See PTAB cases with Daiichi as patent owner |
Drugs and US Patents for Daiichi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 9,675,549 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 9,555,040 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Daiichi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Daiichi | FLOXIN OTIC | ofloxacin | SOLUTION/DROPS;OTIC | 020799-001 | Dec 16, 1997 | 5,401,741 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DAIICHI drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hungary | E048309 | ⤷ Try a Trial |
Costa Rica | 10817 | ⤷ Try a Trial |
Poland | 367532 | ⤷ Try a Trial |
Serbia | 60731 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0206283 | SPC/GB97/085 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
1405852 | 122015000077 | Germany | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
2140867 | 292 50001-2018 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/993 20150623 |
2140867 | PA2018005 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.